$1.46
+2.10%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.46
From 52W high−42.52%
Volume8516.00
Market cap$163.08M
P/E (TTM)—
P/S (TTM)134.1x
Div yield—
Key dataOct 19, 2026
Open
$1.46
From 52W high
−42.52%
Volume
8516.00
Market cap
$163.08M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.0x
P/E (TTM)
—
RSI (14)
37.7
MomentumView details →
1D Return
+2.10%
YTD Return
−16.00%
SummaryUpdated Jun 1, 2026
Innate Pharma S.A. (NASDAQ:IPHA) is a French biotechnology company founded in 1999 and headquartered in Marseille, France. The company went public on NASDAQ in October 2019. Innate Pharma specializes in discovering, developing, and commercializing therapeutic antibodies primarily focused on oncology treatments, with a particular emphasis on leveraging the immune system to fight cancer through innovative approaches including natural killer (NK) cell engagers and antibody-drug conjugates.
Similar companies
Latest newsMore news →
Engitix appointed Sonia Quaratino as Executive Vice President and Chief Medical Officer, a newly created role, effective from her board tenure since 2023.26d agoInnate Pharma's strategic partnership with Sobi to license lacutamab in T-cell lymphoma became effective after antitrust waiting periods expired and closing conditions were met, triggering a USD 75 million payment.33d ago